Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Liquid biopsy could better predict immunotherapy response in lung cancer patients than tumor biopsy

Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure.

3 Jun 2022

Genetically modified herpes virus can be used in the fight against cancer

Viruses can make animals and humans sick - or healthy: Researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB have succeeded in genetically modifying the herpes simplex virus type 1, which triggers painful cold sores, in such a way that it can be used in the fight against cancer in the future.

1 Jun 2022

First-of-its-kind platform generates antitumor immunity and improves responses to checkpoint inhibitors

Researchers at The University of Texas MD Anderson Cancer Center have developed an ultrasound-guided cancer immunotherapy platform that generates systemic antitumor immunity and improves the therapeutic efficacy of immune checkpoint blockade.

30 May 2022

Case Western Reserve signs license agreement to bring groundbreaking AI for helping cancer patients

When Case Western Reserve University research showed that artificial intelligence (AI) could identify which lung cancer patients would benefit from chemotherapy, a national magazine called the finding one of the "10 Most Incredible Medical Breakthroughs of 2018."

25 May 2022

Blood-based biomarker can predict the benefit of immunotherapy to lung cancer patients

A blood-based tumor biomarker can predict the benefit of immunotherapy to patients with non-small cell lung cancer, according to a study published in Nature Medicine.

20 May 2022

Small cell lung cancer subtypes respond differently to chemotherapeutics and targeted drugs

Small cell lung cancer (SCLC) is a malignant disease associated with a particularly high mortality rate. According to a new multicenter study led by MedUni Vienna and conducted in collaboration with researchers from the Czech Republic, Hungary, Slovenia, Sweden and the United States, SCLC can be divided into several subgroups in terms of clinical behavior.

17 May 2022

Study shows effectiveness of point-of-care smoking cessation program for cancer patients

New research in the May 2022 issue of JNCCN - Journal of the National Comprehensive Cancer Network finds the inclusion of the smoking cessation tool Electronic Health Record-Enabled Evidence-Based Smoking Cessation Treatment (ELEVATE, from Epic) into electronic health records (EHRs) can increase self-reported patient quit rates by more than 5 percentage points.

11 May 2022

Study uncovers new regulator of prostate cancer metastasis

A transcription factor normally associated with androgen receptor activity in prostate cancer has a newly discovered role in controlling lipid biosynthesis, according to a Northwestern Medicine study published in Nature Genetics.

10 May 2022

Roswell Park's nursing teams share research at 47th Annual Congress of the Oncology Nursing Society

Several nursing teams from Roswell Park Comprehensive Cancer Center were invited to share their research at the 47th Annual Congress of the Oncology Nursing Society, which is underway in Anaheim, California, and continues through May 1, 2022.

29 Apr 2022

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make the cancer vulnerable.

28 Apr 2022

New data may change the standard of care for patients with advanced non-small cell lung cancer

The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center and participating organizations.

25 Apr 2022

Drug used to treat lung cancer could help improve survival rates for bladder cancer patients

Scientists from the University of Sheffield have discovered a drug already used to treat lung cancer could help to improve survival rates for bladder cancer patients.

11 Apr 2022

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.

11 Apr 2022

Study finds better immunotherapy response in lung cancer patients with genetic variant linked to autoimmune disease

A variant of the CTLA-4 gene associated with autoimmune disease was found to be more frequent in non-small cell lung cancer (NSCLC) patients who experienced an exceptionally high response to anti-PD-1 immunotherapy and higher immune-related side effects than in a comparable cohort of lung cancer patients and healthy individuals, according to data presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

City of Hope's late-breaking clinical trial data to be presented at AACR

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, will present late-breaking and clinical trial findings at this year's American Association for Cancer Research Annual Meeting, which begins today.

8 Apr 2022

New tactic to disrupt cancer repair mechanism could lead to a potential treatment strategy

While cancer therapies targeting specific genes or disease pathways have extended lives, they can also lead to highly resistant tumors when small reservoirs of cancer cells survive treatment, grow, and spread.

30 Mar 2022

Biomarker testing in lung cancer patients has increased in real-world clinical practice, study reveals

More than half of patients diagnosed with advanced non-small cell lung cancer (NSCLC) undergo biomarker testing, and this figure has increased over the last five years, reveal real-world data from a Spanish national registry study reported at the European Lung Cancer Congress, 30 March-2 April 2022.

23 Mar 2022

Researchers receive a combined $1 million grant to study RET-positive lung cancer

University of Colorado Cancer Center member Tejas Patil, MD, is one of three researchers to receive a combined $1 million grant from the Hamoui Foundation and LUNGevity Foundation to study RET-positive lung cancer.

21 Mar 2022

Study finds a promising new target for immunity-boosting cancer treatments

Tumors can use an enzyme called ART1 to thwart antitumor immune cells, making the enzyme a promising new target for immunity-boosting cancer treatments, according to a study from researchers at Weill Cornell Medicine and Albert Einstein College of Medicine.

16 Mar 2022